PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Revenue of $4.5 million for the third quarter 2022, representing a 7% increase from the corresponding period of 2021Sold 23 new instruments in the third quarter, bringing cumulative instruments sold to 277Reduced total operating expenses by 27% from the prior quarter and 37% from Q1, due to continued efforts to streamline operations and enhance productivityPartnered with MediMergent and The Center for Cancer and Bl

BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, New York, NYMulti-Omics Panel on Thursday, November 17th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time Evercore ISI HealthCONx Conference, VirtualFireside Chat on Thursday, December 1st at 12:10 p.m. Eastern Time / 9:10 a.m. Pacific Time A live webcast and replay of the Evercore ISI HealthCONx Conference fireside chat will be available on the "In

BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

BRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the publication of initial data off its CodePlex platform in the journal Scientific Reports carried out by researchers at the Shanghai Institute of Hematology. With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation. In the paper titled "Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence again

BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a partnership with MediMergent, LLC, and The Center for Cancer and Blood Disorders (CCBD), an American Oncology Partners of Maryland practice, to leverage IsoPlexis' single-cell proteomics in a large multi-site study of immuno-compromised cancer patients. The study entitled "Real World Evaluation of the Effectiveness of AZD7442 for Prevention of COVID-19 Infection in Immuno-Suppressed Cancer Patients", will focus on immune cells' functionality and their role in prevention of COVID-19 breakthrough infec

BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. IsoPlexis' management is scheduled to participate in a fireside chat on Monday, September 12th at 4:50 p.m. Eastern Time / 1:50 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.isoplexis.com. About IsoPlexis IsoPlexis is empowering labs, changing the course of human heal

Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00

SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $20.00 from $17.00 previously

SVB Leerink initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $17.00

Cowen & Co. initiated coverage of IsoPlexis with a rating of Outperform

Morgan Stanley initiated coverage of IsoPlexis with a rating of Overweight and set a new price target of $16.00

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

4 - IsoPlexis Corp (0001615055) (Issuer)

15-12G - IsoPlexis Corp (0001615055) (Filer)

8-K - IsoPlexis Corp (0001615055) (Filer)

S-8 POS - IsoPlexis Corp (0001615055) (Filer)

S-8 POS - IsoPlexis Corp (0001615055) (Filer)

25-NSE - IsoPlexis Corp (0001615055) (Subject)

425 - IsoPlexis Corp (0001615055) (Subject)

8-K - IsoPlexis Corp (0001615055) (Filer)

DEFA14A - IsoPlexis Corp (0001615055) (Filer)

425 - IsoPlexis Corp (0001615055) (Subject)

8-K - IsoPlexis Corp (0001615055) (Filer)

BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexisIsoPlexis is the Superhuman Cell company. By leading the discovery and identification of how multi-functional immune—

BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexisIsoPlexis is the Superhuman Cell company. IsoPlexis' systems uniquely identify a comprehensive range of m

BRANFORD, Conn., Oct. 26, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), a leader in functional single-cell proteomics, today announced it will report financial results for the third quarter 2021 before market open on Wednesday, November 10, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. Abo

SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

SC 13G - IsoPlexis Corp (0001615055) (Subject)